<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">282</journal-id><journal-id journal-id-type="pmc-domain">brjpharm</journal-id><journal-id journal-id-type="publisher-id">bph</journal-id><journal-title-group><journal-title>British Journal of Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0007-1188</issn><issn pub-type="epub">1476-5381</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC4337702</article-id><article-id pub-id-type="pmcid-ver">PMC4337702.1</article-id><article-id pub-id-type="pmcaid">4337702</article-id><article-id pub-id-type="pmcaiid">4337702</article-id><article-id pub-id-type="pmid">25363835</article-id><article-id pub-id-type="doi">10.1111/bph.13001</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Papers</subject></subj-group></article-categories><title-group><article-title>AQW051, a novel, potent and selective &#945;7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Feuerbach</surname><given-names initials="D">Dominik</given-names></name><xref ref-type="aff" rid="au1">1</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pezous</surname><given-names initials="N">Nicole</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weiss</surname><given-names initials="M">Markus</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shakeri-Nejad</surname><given-names initials="K">Kasra</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lingenhoehl</surname><given-names initials="K">Kurt</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hoyer</surname><given-names initials="D">Daniel</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hurth</surname><given-names initials="K">Konstanze</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bilbe</surname><given-names initials="G">Graeme</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pryce</surname><given-names initials="CR">Christopher R</given-names></name><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McAllister</surname><given-names initials="K">Kevin</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chaperon</surname><given-names initials="F">Frederique</given-names></name><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kucher</surname><given-names initials="K">Klaus</given-names></name><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Johns</surname><given-names initials="D">Donald</given-names></name><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blaettler</surname><given-names initials="T">Thomas</given-names></name><xref ref-type="aff" rid="au6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lopez Lopez</surname><given-names initials="C">Cristina</given-names></name><xref ref-type="aff" rid="au5">5</xref></contrib><aff id="au1"><label>1</label><institution>Novartis Institutes for BioMedical Research</institution><addr-line>Basel, Switzerland</addr-line></aff><aff id="au2"><label>2</label><institution>Department of Pharmacology and Therapeutics, University of Melbourne</institution><addr-line>Victoria, Australia</addr-line></aff><aff id="au3"><label>3</label><institution>DNDi &#8211; Drugs for Neglected Diseases initiative</institution><addr-line>Geneva, Switzerland</addr-line></aff><aff id="au4"><label>4</label><institution>Department of Psychiatry, Psychotherapy and Psychosomatics, Zurich University Hospital for Psychiatry</institution><addr-line>Zurich, Switzerland</addr-line></aff><aff id="au5"><label>5</label><institution>Translational Medicine Neurosciences, Novartis Pharma AG</institution><addr-line>Basel, Switzerland</addr-line></aff><aff id="au6"><label>6</label><institution>F Hoffmann-La Roche Ltd.</institution><addr-line>Basel, Switzerland</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><bold>Correspondence</bold>, Dominik Feuerbach, Nervous System Research, Novartis Institutes for BioMedical Research, Novartis Pharma AG, WSJ386.9.08.27, CH-4056 Basel, Switzerland. E-mail: <email>dominik.feuerbach@novartis.com</email>, Cristina Lopez Lopez, Translational Medicine Neurosciences, Novartis Pharma AG, Novartis Campus, WSJ-154.4.03, CH-4002 Basel, Switzerland. E-mail: <email>cristina.lopez_lopez@novartis.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>12</day><month>1</month><year>2015</year></pub-date><volume>172</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">249736</issue-id><fpage>1292</fpage><lpage>1304</lpage><history><date date-type="received"><day>27</day><month>6</month><year>2014</year></date><date date-type="rev-recd"><day>14</day><month>10</month><year>2014</year></date><date date-type="accepted"><day>27</day><month>10</month><year>2014</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2016</year></date></event><event event-type="pmc-live"><date><day>01</day><month>03</month><year>2016</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-07-06 05:25:20.687"><day>06</day><month>07</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2014 The British Pharmacological Society</copyright-statement><copyright-year>2014</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bph0172-1292.pdf"/><abstract><sec><title>Background and Purpose</title><p>Activation of the &#945;7 nicotinic ACh receptor (nACh receptor) is considered an attractive target for the treatment of cognitive impairment associated with neurological disorders. Here we describe the novel &#945;7-nACh receptor agonist AQW051 as a promising drug candidate for this indication.</p></sec><sec><title>Experimental Approach</title><p>AQW051 was functionally characterized <italic toggle="yes">in vitro</italic> and cognitive effects evaluated in rodent behavioural models. Pharmacokinetics and tolerability were evaluated in three phase I placebo-controlled studies in 180 healthy subjects.</p></sec><sec><title>Key Results</title><p><italic toggle="yes">In vitro</italic>, AQW051 bound with high affinity to &#945;7-nACh receptors and stimulated calcium influx in cells recombinantly expressing the human &#945;7-nACh receptor. <italic toggle="yes">In vivo</italic>, AQW051 demonstrated good oral bioavailability and rapid penetration into the rodent brain. AQW051 administered over a broad dose range facilitated learning/memory performance in the object recognition and social recognition test in mice and the water maze model in aged rats. Clinically, AQW051 was well tolerated in healthy young and elderly subjects, with an adverse event (AE) profile comparable with placebo. No serious AEs were reported and all AEs were either mild or moderate in severity at single oral doses up to 200&#8201;mg and multiple daily doses up to 75&#8201;mg. Once-daily oral administration of AQW051 resulted in continuous exposure and a two- to threefold accumulation compared with steady state was achieved by 1 week.</p></sec><sec><title>Conclusions and Implications</title><p>These data support further development of AQW051 as a cognitive-enhancing agent, as a therapeutic, for example, in Alzheimer's disease or schizophrenia.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>